Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, Asuragen Team on MDx Kits

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asuragen today said that it has signed a collaboration with Affymetrix to develop RNA Control Kits for molecular diagnostic applications.

Under the agreement, Asuragen will develop and manufacture the kits, which are intended for use with in vitro transcription reagent kits for clinical molecular diagnostic applications, for Affymetrix. The Austin, Texas-based firm said that the kits will enable Affy to supply its molecular diagnostic partners with complete solutions.

In addition, Asuragen noted that the RNA Control Kits will be configured for use on Affy's GeneChip System 3000Dx v.2, which has 510(k) clearance from the US Food and Drug Administration and has the CE Mark in the European Union. The kits make use of Asuragen's expertise in developing and manufacturing multiplexed IVT RNA reagents for use as internal controls, the firm told GenomeWeb Daily News via e-mail.

Asuragen also noted that there are currently more than 20 different molecular assays based on the Affymetrix platform under development by Affymetrix and the 11 partners in its "Powered by Affymetrix" program.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.